“Pancreatic cancer drug-sensitivity predicted by synergy of PAWI-2 and protein biomarker expression”
Potent inhibitor of pancreatic cancer stem cells that synergizes current standard of care, PAWI-2 is featured in Investigational New Drugs.
San Diego, Calif., September 16, 2020 - Researchers at the Human BioMolecular Research Institute and ChemRegen, Inc., reported that a small molecule potently inhibited pancreatic cancer stem cells and also synergized standard of care drugs. Publishing September 15, 2020, in the journal Investigational New Drugs, the team describes how they tested PAWI-2, a man-made, drug-like chemical that can be used to inhibit pancreatic cancer stem cells and other cancer. The researchers discovered PAWI-2 acted as a synergist to make heretofore poorly potent drugs that previously did not show much efficacy in humans work much better in in vitro studies.